Kite teams with GE in bid to lower T cell production costs through automation

Kite Pharma ($KITE) has teamed up with GE Global Research ($GE) to develop an automated production system for engineered T cell therapies. The development of such a system could help Kite control the cost of manufacturing its closely watched autologous immuno-oncology drugs. Dendreon, a pioneer in autologous cancer treatment, was dogged by high manufacturing costs throughout its attempt to make its cancer vaccine Provenge a success. Release

Suggested Articles

There's no evidence personal patient information leaked during the 11-week breach, but the same can't be said about Sangamo's own secrets.

Through a new online tracker, AllTrials names sponsors who fail to report clinical trial results on time per the FDAAA Final Rule.

The new solution aims to streamline the incorporation of human genomic data into clinical trial designs.